文献速递造血干细胞移植与细胞治疗

靶向T细胞四价双特异性抗体治疗移植物抗宿主病

Targeting T cells with tetravalent bispecific antibodies for the treatment of graft-versus-host disease.
PubMed 文献 · Blood Adv · 2025-01-01

本文描述一种基于免疫球蛋白G-[L]-单链可变区片段(IgG-[L]-scFv)平台、四个结合域均靶向CD3的四价T细胞衔接双特异性抗体。体外皮摩尔浓度即可诱导活化CD4和CD8 T细胞裂解;在免疫缺陷小鼠中,0.1 μg/剂可清除外周血大部分T细胞,10 μg/剂完全逆转已建立的GVHD并实现100%生存率。

要点

  • CD3×CD3双特异性抗体在体外皮摩尔浓度下诱导活化CD4和CD8 T细胞裂解。
  • 免疫缺陷小鼠中0.1 μg/剂清除外周血大部分T细胞,10 μg/剂完全逆转GVHD且生存率100%。
  • 30 μg CD3×CD3双特异性抗体组5只小鼠中4只在白血病注射后180天PCR检测不到T细胞。

核心结论

  • CD3×CD3双特异性抗体在免疫缺陷小鼠中可逆转GVHD临床征象并实现长期随访,作者认为需进一步研究其治疗临床GVHD和其他人类自身免疫病的潜力。

研究设计与样本

  • 基于IgG-[L]-scFv平台构建四价T细胞衔接双特异性抗体,四个结合域均靶向CD3;体外实验、免疫缺陷小鼠异种GVHD模型及NALM6-luc异种移植瘤模型。

主要发现

  • 体外皮摩尔浓度CD3×CD3双特异性抗体诱导活化CD4和CD8 T细胞裂解。
  • 免疫缺陷小鼠中0.1 μg/剂清除外周血大部分T细胞,10 μg/剂完全逆转已建立GVHD并实现100%生存率。
  • NALM6-luc异种移植瘤小鼠经CD3×CD19双特异性抗体和活化人T细胞治疗实现白血病完全缓解,所有治疗小鼠在治疗后50天内发生GVHD。
  • CD3×CD3双特异性抗体(3-30 μg剂量)逆转GVHD临床征象,允许超过250天的长期随访。
  • 30 μg CD3×CD3双特异性抗体组5只小鼠中4只在白血病注射后180天PCR检测不到T细胞,第259天完整尸检未见人T细胞或白血病细胞。

关键数值与推荐

  • CD3×CD3双特异性抗体体外诱导活化CD4和CD8 T细胞裂解的浓度为皮摩尔级。
  • 免疫缺陷小鼠中CD3×CD3双特异性抗体0.1 μg/剂清除外周血大部分T细胞,10 μg/剂完全逆转GVHD并实现100%生存率。
  • CD3×CD3双特异性抗体3-30 μg剂量逆转GVHD临床征象,允许超过250天长期随访。
  • 30 μg CD3×CD3双特异性抗体组5只小鼠中4只在白血病注射后180天PCR检测不到T细胞。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文指出需进一步研究以确定CD3×CD3双特异性抗体是否有潜力治疗人类临床GVHD和其他自身免疫病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic stem cell transplantation is an established treatment for hematological malignancies and some genetic diseases. Acute graft-versus-host disease (GVHD) is the most common and debilitating side effect with poor survival rates of 5% to 30% for severe cases. In this manuscript, we describe a tetravalent T-cell-engaging bispecific antibody (BsAb) based on the immunoglobulin G-[L]-single-chain variable fragment (IgG-[L]-scFv) platform, with all 4 binding domains specific for CD3. In vitro, picomolar concentrations of the CD3×CD3 BsAb induced potent lysis of activated CD4 and CD8 T cells. In immunodeficient mice, in which human T cells induced xenogeneic GVHD, administration of 0.1 μg BsAb per dose depleted the majority of T cells from the peripheral blood, and 10 μg per dose completely reversed established GVHD and achieved a 100% survival rate. In mice bearing NALM6-luc xenografts, treatment with CD3×CD19 BsAb and activated human T cells induced complete remission of the leukemia, and all treated mice developed GVHD by 50 days after treatment. CD3×CD3 BsAb (3-30 μg doses) reversed clinical signs of GVHD, allowing long term follow-up beyond 250 days. T cells were undetectable by polymerase chain reaction in 4 of 5 mice in the 30 μg CD3×CD3 BsAb group 180 days after leukemia injection, and complete necropsies on day 259 revealed no evidence of human T cells or leukemia cells. Curing GVHD allows for long-term follow-up of tumor response heretofore impossible in humanized mouse models. Further studies are warranted to determine whether the CD3×CD3 BsAb has potential for treating clinical GVHD and other autoimmune diseases in humans.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Espinosa-Cotton M, Hoseini SS, Miranda IC, et al. Targeting T cells with tetravalent bispecific antibodies for the treatment of graft-versus-host disease. Blood Adv. 2025. PMID: 39293079. doi:10.1182/bloodadvances.2022009187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。